Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of TXA127 in Duchenne muscular dystrophy cardiomyopathy
MOH_2023-06-04_012627Phase 2Not yet recruiting
- Sponsor
- Constant Therapeutics LLC
- Start
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of angiotensin-(1-7) in Duchenne cardiomyopathy (DMD-CM) and Duchenne muscular dystrophy (DMD), sponsored by Constant Therapeutics LLC. Primary endpoint: Safety of TXA127. Planned start May 2023; status: not yet recruiting.
02
Drugs
angiotensin-(1-7)
03
Conditions
Duchenne cardiomyopathy (DMD-CM)Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2023-06-04_012627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-04_012627.